Toripalimab not checked
Coherus Oncology, Inc. · JS001 · TAB-001
FollowEvery change as it happens, and a Monday email
Trials
7 active
10 in total · 3 in the EU
What this is
- How it works
- Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells.Programmed Death Receptor-1 Blocking Antibody FDA class
- How it’s given
- “Participants will receive toripalimab via intravenous infusion (IV) on Day 1 every 3 weeks (Q3W) during the Chemotherapy-based treatment phase and Maintenance treatment phase.”In the company’s words, NCT06457503 on ClinicalTrials.gov
- Tested for
- Advanced Solid Tumor (2 trials), Nasopharyngeal Cancer Recurrent, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumor, Advanced or Metastatic Solid Tumors
- Main trialPhase 4
- “This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.”In the company’s words, NCT06457503 on ClinicalTrials.gov
- Other names
- JS001 · TAB-001 · CHS-007 · Loqtorzi · TAB001
Other drugs for Advanced Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up4
- Sep 2027Phase 2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 4 trial completes · ClinicalTrials.gov
- Jan 2028Phase 1 trial completes · ClinicalTrials.gov
- 30 May 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | Dec 2027 | A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer | |
| Phase 2Active, not recruiting | Sep 2027 | A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | |
| Phase 1Active, not recruiting | 30 Sep 2026 | Study of CHS-114 in Participants With Advanced Solid Tumors | |
| Phase 1Recruiting | Jan 2028 | A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors | |
| Phase 1Not yet recruiting | 30 May 2028 | A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors | |
| Phase 1Terminated | 31 Jul 2024 | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors | |
| Phase 1Completed | 28 May 2025 | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | |
| Phase 3Authorised | not given | A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy | |
| Phase 3Ended | not given | A prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to compare toripalimab (JS001) combined with lenvatinib versus placebo combined with lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC) | |
| Phase 3Authorised | not given | Toripalimab plus chemotherapy as first-line treatment for recurrent and/or metastatic nasopharyngeal cancer: safety and activity in non-endemic population |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026